Home » Stocks » LUMO

Lumos Pharma, Inc. (LUMO)

Stock Price: $12.07 USD 0.14 (1.17%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $12.25 +0.18 (1.49%) Apr 16, 6:53 PM
Market Cap 100.57M
Revenue (ttm) 168,000
Net Income (ttm) -6.31M
Shares Out 8.33M
EPS (ttm) -0.93
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $12.07
Previous Close $11.93
Change ($) 0.14
Change (%) 1.17%
Day's Open 11.93
Day's Range 11.59 - 12.18
Day's Volume 41,389
52-Week Range 7.62 - 36.72

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Virtual KOL Event is scheduled for Tuesday, April 27th @ 10:30 AM ET Virtual KOL Event is scheduled for Tuesday, April 27th @ 10:30 AM ET

3 days ago - GlobeNewsWire

Data show greater GH response in pediatric growth hormone deficiency (PGHD) from LUM-201 than standard GH secretagogues Data show greater GH response in pediatric growth hormone deficiency (PGHD) from L...

4 weeks ago - GlobeNewsWire

There are some investors who buy U.S.-listed equities that are trading below their liquidation value because they are convinced they can gain from these kinds of investments after the market has reasses...

Other stocks mentioned: ASMB, UTSI
4 weeks ago - GuruFocus

AUSTIN, Texas, March 11, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company is pa...

1 month ago - GlobeNewsWire

AUSTIN, Texas, March 09, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for ...

1 month ago - GlobeNewsWire

AUSTIN, Texas, March 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, will present poster 7102 at the ...

1 month ago - GlobeNewsWire

Lumos (LUMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

AUSTIN, Texas, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report it...

1 month ago - GlobeNewsWire

Lumos Pharma appoints new Board member, An van Es-Johansson, M.D., with wealth of experience in rare diseases Lumos Pharma appoints new Board member, An van Es-Johansson, M.D., with wealth of experience...

2 months ago - GlobeNewsWire

Lumos Pharma (LUMO) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

3 months ago - Zacks Investment Research

AUSTIN, Texas, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Lumo s Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company will ...

3 months ago - GlobeNewsWire

AUSTIN, Texas, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company will p...

4 months ago - GlobeNewsWire

Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

AUSTIN, Texas, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for ...

5 months ago - GlobeNewsWire

Lumos (LUMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

AUSTIN, Texas, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company will p...

5 months ago - GlobeNewsWire

AUSTIN, Texas, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report it...

5 months ago - GlobeNewsWire

AUSTIN, Texas, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company wi...

7 months ago - GlobeNewsWire

Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

AUSTIN, Texas, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for...

8 months ago - GlobeNewsWire

AUSTIN, Texas, July 28, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will repor...

8 months ago - GlobeNewsWire

AUSTIN, Texas, July 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that it has e...

8 months ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in Lumos Pharma.

9 months ago - Zacks Investment Research

About LUMO

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2b clinical trial for the treatment of pediatric growth hormone deficiency. The company was founded in 2011 and is headquartered in Austin, Texas.

Industry
Biotechnology
Founded
2011
Stock Exchange
NASDAQ
Ticker Symbol
LUMO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Lumos Pharma stock is "Buy." The 12-month stock price forecast is 31.86, which is an increase of 163.96% from the latest price.

Price Target
$31.86
(163.96% upside)
Analyst Consensus: Buy